2014
Chemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base
Geltzeiler C, Nabavizadeh N, Kim J, Lu K, Billingsley K, Thomas C, Herzig D, Tsikitis V. Chemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base. Annals Of Surgical Oncology 2014, 21: 3616-3620. PMID: 24943237, DOI: 10.1245/s10434-014-3849-5.Peer-Reviewed Original Research
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens